(VIANEWS) – Shares of Arcturus Therapeutics (NASDAQ: ARCT) rose 9.17% to $22.02 at 10:18 EST on Thursday, following the last session’s upward trend. NASDAQ is jumping 1.79% to $11,926.24, following the last session’s upward trend. This seems, so far, an all-around positive trend exchanging session today.
Arcturus Therapeutics’s last close was $20.17, 35.78% under its 52-week high of $31.41.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company's pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U.S., Europe, Japan, China, and other countries. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $-3.55.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.46%.
Volatility
Arcturus Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was 8.20%, 1.43%, and 3.29%.
Arcturus Therapeutics’s highest amplitude of average volatility was 9.33% (last week), 4.67% (last month), and 3.29% (last quarter).
Moving Average
Arcturus Therapeutics’s worth is way above its 50-day moving average of $18.12 and way above its 200-day moving average of $17.24.
Previous days news about Arcturus Therapeutics (ARCT)
- Arcturus therapeutics (arct) beats Q4 earnings and revenue estimates. According to Zacks on Tuesday, 28 March, "While Arcturus Therapeutics has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about Arcturus Therapeutics (ARCT).
